期刊文献+

Cytokines in new-onset refractory status epilepticus:ready for clinical use?

原文传递
导出
摘要 New-onset refractory status epilepticus(NORSE)is a rare and challenging condition characterized by refractory status epilepticus in an otherwise healthy patient without obvious causes.Increasing evidence suggests a change in cytokine profiles in NORSE.However,the clinical utility of cytokine testing remains uncertain,primarily because of the lack of robust study designs and limited sample sizes.A recent study published in Annals of Neurology investigated the cytokine profiles in both serum and cerebrospinal fluid samples of NORSE patients.The study found elevated levels of CXCL8,CCL2,and MIP-1αin the serum and elevated levels of IL-1ßin the cerebrospinal fluid of NORSE patients compared to those with other forms of refractory status epilepticus(RSE).Furthermore,patients with cryptogenic NORSE had even higher levels of CXCL8,CCL2,and MIP-1αin the serum.Patients with NORSE who exhibited elevated levels of innate immunity cytokines in the serum had worse outcomes at discharge and several months after the NORSE ended.In summary,these findings highlight the association between inflammation-related cytokines and NORSE,providing new insights into clinical diagnosis and treatment approaches.
出处 《Acta Epileptologica》 2024年第3期249-251,共3页 癫痫学报(英文)
基金 National Natural Science Foundation of China(82201607).
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部